Keywords: alkermes, stops, cereport, trial, discontinued, phase, iii
Alkermes stops Cereport trial
Article | 08 April 1999
Alkermes has discontinued a Phase III trial of Cereport (RMP-7) inpatients with newly-diagnosed, high-grade glioblastoma multiforme, although it has stressed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
